Fulgent Genetics, Inc. (FLGT): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$66.97M

Year ended 2025-12-31

-$96.46M

Trailing 12 months to 2026-06-30

2019-12-31 EBITDA (USD) 2025-12-31

Period ended	EBITDA	Change YoY	Source filing
2025-12-31	-$66.97M	n/m	2026-02-27, From 2025-01-01
2024-12-31	-$48.99M	n/m	2026-02-27, From 2024-01-01
2023-12-31	-$169.39M	n/m	2026-02-27, From 2023-01-01
2022-12-31	$211.19M	-69.3%	2025-02-28, From 2022-01-01
2021-12-31	$686.96M	+134.4%	2024-02-28, From 2021-01-01
2020-12-31	$293.12M	n/m	2023-02-28, From 2020-01-01
2019-12-31	$1.68M	n/a	2022-02-28, From 2019-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EBITDA	Change YoY
Fulgent Genetics, Inc. (FLGT)	2025-12-31	-$66.97M	n/m
BillionToOne, Inc. (BLLN)	2025-12-31	$22.92M	n/m
Castle Biosciences Inc (CSTL)	2025-12-31	-$2.04M	n/m
CareDx, Inc. (CDNA)	2025-12-31	-$15.76M	n/m
Veracyte, Inc. (VCYT)	2025-12-31	$79.19M	+100.0%
Caris Life Sciences, Inc. (CAI)	2025-12-31	$67.73M	n/m
Guardant Health, Inc. (GH)	2025-12-31	-$397.51M	n/m
Biodesix Inc (BDSX)	2025-12-31	-$22.20M	n/m
Personalis, Inc. (PSNL)	2025-12-31	-$78.01M	n/m

Compare FLGT, BLLN, CSTL, CDNA side by side · Screen every company in Services-Medical Laboratories ↗